Trials / Completed
CompletedNCT05684484
Role of Roflumilast in Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 15 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This study aims to investigate possible efficacy and safety of Roflumilast in adult patients with ulcerative colitis disease .
Detailed description
* Study design and study population This study will be randomized, controlled, parallel study. * It will be conducted on 52 patient having with mild to moderate degree ulcerative colitis disease divided into two groups 1. Group 1 (n=26): Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid) for 3 months. 2. Group 2 (n=26): Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months * Patient will be selected from Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital. * A written informed consent will be obtained from all patients * This study will be approved by the Research Ethics Committee of Tanta University. * Any unexpected risks appeared during the course of research will be reported to the participants and ethical committee on time and documented through an adverse effects reporting form . * Randomization will be carried out based on days of hospital admission
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roflumilast 500 MCG Oral Tablet [DALIRESP] | Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders |
| DRUG | amino salicylic acid | conventional treatment |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2024-04-15
- Completion
- 2024-09-15
- First posted
- 2023-01-13
- Last updated
- 2025-01-28
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05684484. Inclusion in this directory is not an endorsement.